Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
Category: #health  By Paroma Bhattacharya  Date: 2019-10-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech IMbrave150 study meets coprimary endpoints for HCC treatment

With growing occurrence of liver cancer cases across the globe, the need to find a solution to the ailment is rising steadily among global biotechnology and pharmaceutical firms. Various clinical trials and studies are increasingly being conducted to discover an effective treatment over this cancer.

Genentech Inc, a renowned U.S. based biotechnology company and a subsidiary of Roche Group, reportedly announced that its Phase III IMbrave150 trial, evaluating combination of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) to treat people suffering from unresectable HCC (hepatocellular carcinoma), who did not receive any prior systemic therapy.

The treatment met both of the study’s co-primary endpoints, showcasing clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) when compared to standard-of-care sorafenib. 

Safety for the Avastin and Tecentriq combination was observed to be consistent with the pre-known safety profiles of individual medicines, with no identification of new safety signals. IMbrave150 trial data would be showcased during a forthcoming medical meeting.   

Chief Medical Officer and Head of Global Product Development, Levi Garraway, M.D., Ph.D., stated that the company is thrilled with the outcomes of its study assessing the Tecentriq-Avastin combination, which becomes the first therapy in over a decade to enhance overall survival in patients suffering from unresectable hepatocellular carcinoma who did not undergo any prior systemic therapy.       

Garraway added that HCC is a prominent cause of death across the world, specifically in Asia, which makes this study a vital step in the company’s mission to address unmet medical demands for patients across the globe. The company would submit data from the study to global health authorities soon. The company expects to bring a novel treatment to people suffering with this serious disease who presently have limited options.        

Earlier in July of 2018, the U.S. FDA (Food and Drug Administration) granted Tecentriq-Avastin combination the BTD (Breakthrough Therapy Designation) in hepatocellular carcinoma on the basis of data collected from a currently ongoing Phase Ib clinical trial.

Genentech has made an extensive development program specially for Tecentriq, which includes several planned and ongoing Phase III studies, in skin, gynecological, gastrointestinal, breast, genitourinary, lung, neck and head cancers. This also includes trials evaluating Tecentriq in combination with other medicines as well as alone.     

Earlier in September, the biotechnology firm had announced its plan to double its workforce from 15,000 to 30,000 workers under its expansion plan.

 

Source credit: https://www.gene.com/media/press-releases/14818/2019-10-20/genentechs-tecentriq-in-combination-with



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...